Gilead to acquire CGI Pharmaceuticals for up to $120 million
This article was originally published in Scrip
Executive Summary
The US biopharmaceutical company Gilead Sciences is strengthening its hand in protein kinase biology by acquiring CGI Pharmaceuticals for up to $120 million in cash.